Signs of progress in gene therapy for muscular dystrophy also warrant caution

Molecular Therapy

Volumn 20, Issue 2, 2012, Pages 249-251

  Stedman, Hansell H ^a,c   Byrne, Barry J ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c Stellar Chance Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; VIRUS ANTIBODY;

ADENO ASSOCIATED VIRUS; ANTIBODY TITER; ANTIGEN BINDING; CLINICAL EFFECTIVENESS; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; INJECTION SITE EXTRAVASATION; MUTATION RATE; NONHUMAN; NOTE; PATIENT SAFETY; PETECHIA; RISK BENEFIT ANALYSIS; SYSTEMIC THERAPY; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 84856558657     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.307     Document Type: Note

References (21)

1. Wang, B, Li, J and Xiao, X (2002). Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci USA 97: 13714-13719.
2. Bowles, DE, McPhee, SWJ, Li, C, Gray, SJ, Samulski, JJ, Camp, AS et al. (2012). Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther 20: 443-455.
3. Fan, Z, Kocis, K, Valley, R, Howard, JF, Chopra, M, An, H et al. (2012). Safety and feasibility of high-pressure transvenous limb perfusion with 0.9% saline in human muscular dystrophy. Mol Ther 20: 456-461.
4. Monaco, AP, Neve, RL, Colletti-Feener, C, Bertelson, CJ, Kurnit, DM and Kunkel, LM (1986). Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 323: 646-650. (Pubitemid 16008561)
5. Koenig, M, Monaco, AP and Kunkel, LM (1988). The complete sequence of dystrophin predicts a rodshaped cytoskeletal protein. Cell 53: 219-226.
6. Hoffman, EP, Brown, RH, Jr. and Kunkel, LM (1987). Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51: 919-928.
7. Cox, GA, Cole, NM, Matsumura, K, Phelps, SF, Hauschka, SD, Campbell, KP et al. (1993). Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature 364: 725-729. (Pubitemid 23273127)
8. Acsadi, G, Dickson, G, Love, DR, Jani, A, Walsh, FS, Gurusinghe, A et al. (1991). Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs. Nature 352: 815-818. (Pubitemid 21912438)
9. England, SB, Nicholson, LVB, Johnson, MA, Forrest, SM, Love, DR, Zubrzycka-Gaarn, EE et al. (1990). Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343: 180-182.
10. Qiao, C, Li, J, Zhu, T, Draviam, R, Watkins, S, Ye, X et al. (2005). Amelioration of laminin-alpha2-deficient congenital muscular dystrophy by somatic gene transfer of miniagrin. Proc Natl Acad Sci USA 102: 11999-12004. (Pubitemid 41291118)
11. Gregorevic, P, Allen, JM, Minami, E, Blankinship, MJ, Haraguchi, M, Meuse, L et al. (2006). rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 12: 787-789. (Pubitemid 44050067)
12. Mendell, JR, Campbell, K, Rodino-Klapac, L, Sahenk, Z, Shilling, C, Lewis, S et al. (2010). Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 363: 1429-1437.
13. Wang, Z, Tapscott, SJ, Chamberlain, JS and Storb, R (2011). Immunity and AAV-mediated gene therapy for muscular dystrophies in large animal models and human trials. Front Microbiol 2: 201.
14. Haldane, JBS (1927). On being the right size. Possible Worlds and Other Essays. Chatto & Windus: London, pp 20-28.
15. Arruda, VR, Stedman, HH, Nichols, TC, Haskins, ME, Nicholson, M, Herzog, RW et al. (2005). Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood 105: 3458-3464. (Pubitemid 40628186)
16. Su, LT, Gopal, K, Wang, Z, Yin, X, Nelson, A, Kozyak, BW et al. (2005). Uniform scale-independent gene transfer to striated muscle after transvenular extravasation of vector. Circulation 112: 1780-1788. (Pubitemid 41368154)
17. Kornegay, JN, Li, J, Bogan, JR, Bogan, DJ, Chen, C, Zheng, H et al. (2010). Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol Ther 18: 1501-1508.
18. White, JD, Thesier, DM, Swain, JB, Katz, MG, Tomasulo, C, Henderson, A et al. (2011). Myocardial gene delivery using molecular cardiac surgery with recombinant adeno-associated virus vectors in vivo. Gene Ther 18: 546-552.
19. Gwathmey, JK, Yerevanian, AI and Hajjar, RJ (2011). Cardiac gene therapy with SERCA2a: from bench to bedside. J Mol Cell Cardiol 50: 803-812.
20. Goonasekera, SA, Lam, CK, Millay, DP, Sargent, MA, Hajjar, RJ, Kranias, EG et al. (2011). Mitigation of muscular dystrophy in mice by SERCA overexpression in skeletal muscle. J Clin Invest 121: 1044-1052.
21. Nathwani, AC, Tuddenham, EG, Rangarajan, S, Rosales, C, McIntosh, J, Linch, DC et al. (2011). Adenovirusassociated virus vector-mediated gene transfer in hemophilia. N Engl J Med; e-pub ahead of print 10 December 2011.